BenchSci
BenchSci develops ASCEND, a GenAI platform designed to accelerate drug discovery by integrating a multi-modal AI evidence engine and comprehensive biomedical datasets.
GenAI Platform ASCEND by BenchSci
BenchSci developed ASCEND, a generative AI platform aimed at expediting drug discovery and intricate research workflows across various therapeutic areas. ASCEND is powered by a multimodal AI evidence engine, which is built from ontologies designed to understand complex biomedical experiments. This platform leverages cutting-edge AI technology to interpret experiments from both textual and visual data sources, enhancing the depth and breadth of research insights.
Comprehensive Biomedical Dataset
BenchSci offers access to a robust biomedical dataset that includes closed-access papers, patents, preprints, and third-party data. This extensive data collection ensures that researchers have the information they need to advance their studies. By integrating diverse and comprehensive data sources, BenchSci helps streamline and optimize the research process, making valuable information more accessible.
Enterprise-Grade Software Solutions
BenchSci provides scalable, enterprise-grade software solutions tailored to accommodate previously unmapped workflows in the pharmaceutical industry. These solutions are designed with enterprise-grade security to meet the stringent requirements of internal pharma data integrations. BenchSci’s software is equipped to handle data across all therapeutic areas, ensuring that it can support a wide range of research and development activities.
AI-Powered Biomedical Experiment Understanding
BenchSci employs biology-specific multimodal AI to enhance the understanding of biomedical experiments. This technology is capable of extracting insights from both text and figures, offering a holistic view of experimental data. By utilizing this advanced AI, BenchSci enables researchers to derive more meaningful interpretations from complex experiments, aiding in the discovery and development of novel therapeutics.
Series D Funding for Drug Discovery Innovation
BenchSci raised $95 million in Series D funding, which will be used to further develop its AI platform ASCEND and drive innovation in drug discovery. This significant investment highlights the confidence in ASCEND's potential to revolutionize the field of pharmaceutical research. The funding will support the enhancement and expansion of BenchSci’s platform, enabling more efficient and effective drug discovery processes.